Skip to main content

Market Overview

Moderna Stock Drops As Q1 Sales Fails To Meet Expectations; Anticipates $19.2B In FY21 Product Sales

Moderna Stock Drops As Q1 Sales Fails To Meet Expectations; Anticipates $19.2B In FY21 Product Sales
  • Moderna Inc (NASDAQ: MRNAreports Q1 EPS of $2.84, a turnaround from EPS loss of $0.35 a year ago, beating the consensus estimate of $2.39.
  • However, Q1 revenues of $1.9 billion compared to $8 million a year ago fell short of the $2.04 billion consensus.
  • The stupendous sales growth was primarily attributable to commercial sales of its COVID-19 vaccine of $1.7 billion, and 102 million doses were recognized as revenue.
  • Operating income came in at 1.3 billion compared to a loss of $131 million.
  • It held cash and equivalents were $8.2 billion and generated an operating cash flow of $3.0 billion.
  • Guidance: For FY21, the company has already signed Advance Purchase Agreements for scheduled delivery for a total of $19.2 billion in anticipated product sales, including sales already recorded in this March quarter.
  • It expects to deliver 200-250 million doses of its COVID-19 shots in Q2.
  • Moderna also sees higher R&D and SG&A expenses during 2021 as commercial, R&D activities, and costs ramp up.
  • Yesterday, a single booster dose of Moderna's COVID-19 vaccine generated a favorable immune response against variants first identified in South Africa and Brazil.
  • Price Action: MRNA shares dropped 5.8% at $153.36 during the premarket session on the last check Thursday.

Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 VaccineEarnings News Guidance Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at